[CAS NO. 300832-84-2] Ciluprevir
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [300832-84-2]
Catalog
HY-10242
Brand
MCE
CAS
300832-84-2
DESCRIPTION [300832-84-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 774.93 |
| Molecular Formula | C40H50N6O8S |
| SMILES | O=C1N2C[C@@H](C[C@]2(C(N[C@@]3(C[C@]3(/C=C\CCCCC[C@@H]1NC(OC4CCCC4)=O)[H])C(O)=O)=O)[H])OC5=CC(C6=CSC(NC(C)C)=N6)=NC7=CC(OC)=CC=C75 |
For research use only. We do not sell to patients.
Summary
Ciluprevir(BILN 2061) is a specific and potent peptidomimetic inhibitor of the HCV NS3 protease with an IC 50 of 3.0 nM.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02226952 | Boehringer Ingelheim |
Hepatitis C, Chronic
|
November 2001 | Phase 1|Phase 2 |
| NCT02226939 | Boehringer Ingelheim |
Liver Cirrhosis|Hepatitis C, Chronic
|
September 2002 | Phase 2 |
| NCT02268760 | Boehringer Ingelheim |
Healthy
|
June 2001 | Phase 1 |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Llinàs-Brunet M, et al. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. J Med Chem. 2004 Mar 25;47(7):1605-8.
- [2] Thibeault D, et al. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J Virol. 2004 Jul;78(14):7352-9.
- [3] Lamarre D, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003 Nov 13;426(6963):186-9.
- [4] Reiser M, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005 Apr;41(4):832-5.
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.